Warning: count(): Parameter must be an array or an object that implements Countable in /home/logicben/public_html/drugtrialsformoney.com/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 391

Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome

Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome
Conditions:   Blasts More Than 5 Percent of Bone Marrow Nucleated Cells;   Chronic Myelomonocytic Leukemia;   Recurrent High Risk Myelodysplastic Syndrome;   Recurrent Myelodysplastic Syndrome;   Refractory High Risk Myelodysplastic Syndrome;   Therapy-Related Myelodysplastic Syndrome
Interventions:   Drug: Azacitidine;   Drug: Venetoclax
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

November 13, 2019 / by / in
Comments